Free tool
FAERS Monitor: Symproic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208854 or its brand name (Symproic, Naldemedine Tosylate). Reports on generic versions are filed under their own applications.
Reports
1,662
Serious
1,228
74% of reports
Hospitalization
698
Death reported
465
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea191
- nausea132
- constipation111
- drug ineffective111
- malignant neoplasm progression98
- abdominal pain92
- interstitial lung disease81
- decreased appetite78
- malaise69
- anaemia65
- pyrexia64
- vomiting60
- off label use55
- hepatic function abnormal54
- febrile neutropenia50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 4 |
| 2015 | 2 |
| 2017 | 65 |
| 2018 | 371 |
| 2019 | 196 |
| 2020 | 132 |
| 2021 | 134 |
| 2022 | 189 |
| 2023 | 143 |
| 2024 | 156 |
| 2025 | 168 |
| 2026 | 101 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,497 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| interstitial lung diseaseSignal | 81 | 21.2 | 17.1 | 1,540 |
| hepatic function abnormalSignal | 54 | 18.3 | 14.1 | 868 |
| malignant neoplasm progressionSignal | 98 | 12.1 | 10.0 | 993 |
| febrile neutropeniaSignal | 50 | 9.5 | 7.3 | 375 |
| constipationSignal | 111 | 6.4 | 5.4 | 510 |
| abdominal painSignal | 92 | 5.0 | 4.1 | 294 |
| anaemiaSignal | 65 | 4.3 | 3.4 | 164 |
| decreased appetiteSignal | 78 | 4.3 | 3.4 | 193 |
| diarrhoeaSignal | 191 | 3.7 | 3.3 | 394 |
| pyrexiaSignal | 64 | 2.3 | 1.8 | 49 |
| nauseaSignal | 132 | 2.1 | 1.8 | 79 |
| malaise | 69 | 2.0 | 1.6 | 34 |
| vomiting | 60 | 1.6 | 1.3 | 14 |
| drug ineffective | 111 | 1.1 | 0.9 | 0 |
| off label use | 55 | 0.8 | 0.6 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.